QUANTRO Therapeutics Extends Cancer Collaboration with Boehringer Ingelheim

QUANTRO Therapeutics GmbH, a leader in transcription factor targeting cancer treatments, has announced a two-year extension of its collaboration with Boehringer Ingelheim. This collaboration, first established in 2022, focuses on developing first-in-class drug candidates to address unmet needs in cancer treatment. The extension follows the successful identification of novel drug targets using QUANTRO's high-throughput screening technology.

Under the agreement, QUANTRO is eligible for up to €500 million in milestone payments. The partnership aims to advance therapeutics that target mechanisms previously considered undruggable, offering new hope for cancer patients with limited treatment options.

QUANTRO's proprietary transcriptomics platform allows precise characterization of transcriptional responses, crucial in understanding cancer biology. This platform has led to significant progress, including the successful evaluation of over 350,000 compounds.